MedTrace Logo

Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma

NCT01393756 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-12-05

No results posted yet for this study

Summary

The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone) in a population of patients with follicular lymphoma as measured by the response rate at the end of treatment.

Conditions

Interventions

DRUG

Lenalidomide and R-CHOP

Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.

Sponsors & Collaborators

  • Centre Henri Becquerel

    collaborator OTHER

  • The Lymphoma Academic Research Organisation

    lead OTHER

Principal Investigators

  • Hervé TILLY, Professeur · Lymphoma Study Association

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-07-31
Completion
2015-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01393756 on ClinicalTrials.gov